IRIDEX Corp.

As of November 3, 2016, IRIDEX Corp. is considered overvalued and risky due to poor financial metrics, including a Price to Book Value of 16.34 and negative EV to EBIT and EV to EBITDA ratios, which indicate significant profitability challenges compared to its peers.

As of November 3, 2016, IRIDEX Corp. is considered risky and overvalued due to its high Price to Book Value of 16.34 and negative financial metrics, contrasting sharply with peers like Kewaunee Scientific Corp., which has a favorable P/E ratio of 5.90.

As of June 17, 2025, the market trend is bearish with moderate strength, indicated by daily moving averages and longer-term indicators, despite some mild bullish signals in the weekly timeframe.

As of March 2022, the management team of IRIDEX Corp. includes Mr. Robert Gunst (Independent Chairman), Mr. David Bruce (President and CEO), and several Independent Directors: Ms. Doris Engibous, Dr. Robert Grove, Mr. Kenneth Ludlum, and Mr. Scott Shuda. This team provides governance and strategic direction for the company.

IRIDEX Corporation develops therapeutic laser consoles and devices for treating eye diseases, operating in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $12 million and a market cap of $16.35 million.

As of Jun 18, IRIDEX Corp. has a market capitalization of 16.35 million and reported net sales of 48.81 million with a net profit of -7.13 million over the latest four quarters. Shareholder's funds are 2.10 million, and total assets amount to 29.14 million.